A musculoskeletal disorder characterised by tenderness, widespread chronic pain, and often accompanied by other comorbid conditions such as depression, anxiety, chronic fatigue is termed fibromyalgia (FM). A patent review was aimed to survey patents of new drugs and alternative therapies for FM. The new therapeutic patents on FM treatment published from 2010 to 2017 in WIPO, DERWENT, INPI, ESPANET, and USPTO reviewed. It was found that some of the therapeutic agents in pre-clinical phases has unclear clinical applicability. Some other therapeutic approaches were seen such as well-established drugs in the market in combination or drug repositioning that combines the new analgesic effects with the old side effects. Further studies on safety and efficacy of such agents should be carried out to implement them to FM treatment.